188 related articles for article (PubMed ID: 35819743)
1. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
Wang Z; He T; Yu D; Qin X; Geng A; Yang H
Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
[TBL] [Abstract][Full Text] [Related]
3. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
4. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.
Xu C; Xie X; Kang N; Jiang H
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study.
Wang C; Wang Z; Zhao Y; Wang F
J Gastric Cancer; 2023 Apr; 23(2):328-339. PubMed ID: 37129156
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.
Lin JX; Xu YC; Lin W; Xue FQ; Ye JX; Zang WD; Cai LS; You J; Xu JH; Cai JC; Tang YH; Xie JW; Li P; Zheng CH; Huang CM
JAMA Netw Open; 2021 Jul; 4(7):e2116240. PubMed ID: 34241629
[TBL] [Abstract][Full Text] [Related]
7. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
8. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
10. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.
Tang Z; Wang Y; Yu Y; Cui Y; Liang L; Xu C; Shen Z; Shen K; Wang X; Liu T; Sun Y
BMC Med; 2022 Apr; 20(1):107. PubMed ID: 35382819
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Yang H; Geng A; Wang Z; Wu C
J Obstet Gynaecol Res; 2023 Jun; 49(6):1611-1619. PubMed ID: 36988159
[TBL] [Abstract][Full Text] [Related]
12. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
14. Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer.
Xiong H; Li Y
Am J Cancer Res; 2023; 13(8):3559-3570. PubMed ID: 37693166
[TBL] [Abstract][Full Text] [Related]
15. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
Zheng Y; Yang X; Yan C; Feng R; Sah BK; Yang Z; Zhu Z; Liu W; Xu W; Ni Z; Beeharry MK; Hua Z; Yan M; Zhu Z; Li C
Eur J Cancer; 2020 May; 130():12-19. PubMed ID: 32171104
[TBL] [Abstract][Full Text] [Related]
16. [Safety and short-term efficacy of apatinib combined with oxaliplatin and S-1 in the conversion treatment for gastric cancer with peritoneal metastasis].
Ye ZS; Zeng Y; Wei SH; Wang Y; Chen S; Lin ZT; Wang ZW; Chen XL; Chen LC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):240-247. PubMed ID: 34645168
[No Abstract] [Full Text] [Related]
17. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhao J; He M; Li J; Li D; Zhao Y; Li X; Zhang X; Chen X; Liu Y; Zhao L
Cancer Biother Radiopharm; 2022 May; 37(4):324-331. PubMed ID: 34524004
[No Abstract] [Full Text] [Related]
18. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]